Main contents starts here
Press Releases 2008
- May 9, 2008
Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period - May 9, 2008
Notice regarding Acquisition of the Company’s own shares
(Under the provisions of Articles of Incorporation pursuant to Article 165 (2) of the Corporation Law of Japan) - May 1, 2008
Abbott, Takeda Conclude TAP Joint Venture - April 30, 2008
Sucampo Pharmaceuticals Obtains FDA Approval for AMITIZA® for the Treatment of Irritable Bowel Syndrome with Constipation in Adult Women
Sucampo Pharmaceuticals’ Second Consecutive Successful FDA Approval for AMITIZA; 8 mcg Dose to Fill the Void in the Currently Available Therapies for IBS-C in Adult Women - April 25, 2008
Notice Concerning Cancellation of Own Shares - April 25, 2008
Notice of Execution of Acquisition of the Company’s Own Shares - April 10, 2008
Notice regarding Acquisition of the Company’s own shares
(Under the provisions of Articles of Incorporation pursuant to Article 165 (2) of the Corporation Law of Japan) - April 10, 2008
Takeda to Acquire Millennium for Us$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
-- Acquisition Accelerates Takeda’s Vision of Becoming a Global Leader in Oncology -- - April 4, 2008
Takeda Wins Definitive Decision in Patent Infringement Litigation on Appeal against an ANDA Filer for Generic ACTOS® - April 1, 2008
Transfer of Shares of Hitachi Inspharma, Ltd. from Takeda to Hitachi - April 1, 2008
Launch of Takeda Bio Development Center Limited - April 1, 2008
New Data Showed ACTOS® (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients with Type 2 Diabetes
Data expands body of evidence in high risk population using IVUS, a unique marker for coronary atherosclerosis - April 1, 2008
Cell Genesys and Takeda Announce Global Alliance for the Development and Commercialization of GVAX Immunotherapy for Prostate Cancer - March 31, 2008
Sharing of Sabin-IPV Seed Virus by Japan Poliomyelitis Research Institute with Takeda and Grant of Right to Its Commercialization - March 28, 2008
Discontinuation of Development of TAK-475, A Compound for Treatment of Hypercholesterolemia - March 20, 2008
Announcement on the Restructuring of U.S. Operations - March 20, 2008
Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
Companies to Evenly Divide Value of TAP - March 17, 2008
Takeda Submitted a New Drug Application for a Fixed Dose Combination Tablet of Blopress® with Diuretic in Japan for Treatment of Hypertension - February 29, 2008
Takeda Submitted a New Drug Application for Ramelteon in Japan for Treatment of insomnia - February 18, 2008
Takeda Discontinues Development of Matuzumab - February 4, 2008
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates - January 25, 2008
Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide™ to Treat Chemotherapy Induced Anemia - January 4, 2008
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. - January 4, 2008
TAP Pharmaceutical Products Inc. Filed New Drug Application for TAK-390MR in Patients with Acid-Related Disorders